Objective: Evidence has been presented that in both animals and humans the rebound secretion of growth hormone (GH) following withdrawal of an infusion of somatostatin (SS) is due to the functional activation of the hypothalamic GH-releasing hormone (GHRH) neurons of the recipient organism. Based on this premise, this study has sought to assess the existence of functional interactions between endogenous GHRH released by a SS infusion withdrawal (SSIW) and growth hormone-releasing peptides (GHRPs), a class of compounds allegedly acting via GHRH. Methods: Five young dogs (3 to 4 years old, 2 male and 3 female) were administered, on different occasions, three consecutive intravenous boli of physiological saline (0.1 ml/kg), or GHRH (2 mg/kg), or EP92632 (125 mg/kg), a GHRP compound, or GHRH plus EP92632 at the end of three cycles of 1-h SS infusions (8 mg/(kgÂh)) or during a 6-h infusion of saline. Results: Under saline infusion (SALI), plasma GH levels were unaltered, whereas each SSIW cycle was followed by similar GH secretory episodes. Administration of the ®rst GHRH bolus under SALI induced a rise in plasma GH concentrations slightly higher than that induced by the ®rst cycle of SSIW, but the GH response to the second and third GHRH boli was similar to that after SSIW. Following SSIW, the response to the ®rst bolus of GHRH was higher than that during SALI, but the second and third cycles of SSIW induced GH responses similar to those evoked by the GHRH bolus. During SALI, administration of the ®rst bolus of EP92632 induced a rise in plasma GH which was higher than that induced by the ®rst GHRH bolus, the second bolus elicited a GH peak of lesser amplitude and there was a partial restoration of the GH response to the third peptide bolus. SSIW strikingly enhanced the GH release to the ®rst EP92632 bolus, a pattern also present, although to a lesser extent, with the second and third cycles of SSIW. Under SALI, combined administration of GHRH and EP92632 had a synergistic effect on GH release, but a progressive reduction was present in the GH response to the second and third GHRH plus EP92632 boli. SSIW increased only weakly the GH response to the ®rst co-administration of the peptides over that present after administration of EP92632 alone, and did not induce a GH response higher than that present during SALI when the second bolus of the peptides was administered; after the third SSIW a GH rise higher than that present during SALI was elicited by the combined administration of the peptides. Conclusions: (i) the uniformity of the GH rebound responses to multiple cycles of SSIW may indicate that the latter activate a physiological mechanism which mimics that normally controlling GH pulse generation; (ii) EP92632 elicits, under our experimental conditions, a plasma GH rise higher than that induced by GHRH; (iii) SSIW enhances the GH response to EP92639 alone, to an extent reminiscent of that following combined administration of GHRH and EP92632. This pattern reinforces the view that SSIW elicits release of endogenous GHRH, and infers that the GHRP challenge after SSIW may be exploited in humans to distinguish between healthy and GH-de®cient adults.
Introduction
A great many studies in animals and humans have provided evidence that somatostatin (SS) and growth hormone-releasing hormone (GHRH) are essential regulators of the secretion of growth hormone (GH), and that hypothalamic SS tone dictates the pituitary responsiveness to repeated GHRH challenges (1±4). The GH secretory burst generated appears to be important in enhancing SS release, particularly during the trough period encountered in spontaneous GH secretory studies (negative GH auto-feedback) (5±6).
New complexity to our understanding of the neuroregulation of GH has been added by the development of a new class of peptides, the GH-releasing peptides (GHRPs) (7±11). They are potent GH releasers (12), act via speci®c receptor sites in both the hypothalamus and the pituitary (13±15) (divorced from GHRH receptor sites (16)) and for which an endogenous ligand, Grelin, has recently been identi®ed (17±19). Several lines of evidence have indicated that in vivo and in vitro GH responsiveness to GHRPs is dependent on GHRH function (6, 12), whereas the functional interactions of SS with GHRPs have not been so extensively studied and appear more elusive. Somatostatin could inhibit GH response to GHRP by a hypothalamic (20) as well as a pituitary action (21, 22) , and SS and GHRPs could act at either site as mutual functional antagonists (7, 23).
In recent years, studies in animals and humans have provided evidence that the rebound GH rise which follows withdrawal of an infusion of SS is due, at least in part, to the functional activation of GHRH neurons of the recipient organism (24±29). Thus, SS infusion withdrawal (SSIW) may represent a test to probe, inferentially, endogenous GHRH function, and may provide a potential tool in the diagnosis of growth disorders due to GH hyposecretory states (30) or to assess the declining GHRH function in ageing (29) .
The rebound GH rise which follows SSIW could be magni®ed by the administration before SS withdrawal of GHRH (27, 28, 31) , implying that the SSIW approach might also be exploited to investigate in vivo the functional interaction between endogenous GHRH and GHRPs.
With this in mind, we studied the functional interactions between endogenous GHRH and GHRPs in the dog, a species which behaves like humans in most aspects of GH neuroregulation (32) . Dogs were exposed to three consecutive SSIW cycles and were given at the end of each cycle GHRH, a GHRP peptide, or a combination of both; the timing and extent of the rebound GH rise were investigated.
Materials and methods

Animals
Five young well-trained beagle dogs (3±4 years old, 2 male and 3 female), weighing between 8±15 kg, were used. They were exercised routinely and were fed normal dry food (Diete Standard, Charles River, Calco, Italy) once a day at 1600 h, with water available ad libitum. They were on a 12-h light:12-h darkness regimen, with lights on at 0700 h. At the beginning of the study, body weights of the dogs were stable and they had no observable diseases. All experiments were carried out in conscious animals. Before the experiments, animals were kept at rest in the laboratory for at least 1 h.
Experiments on each dog were scheduled in a randomized order, at least 1 week apart, with continued training.
All the experiments were performed in accordance with protocols previously authorized by the Committee on Animal Care and Use of the University of Milan.
Study design
Following an overnight fast, two indwelling intravenous cannulae were inserted in the forearms at 0830 h (t 230 ). One cannula was used for slow intravenous infusion of saline or SS (see below), which was commenced at t 0 , and the other for bolus administration of saline or compounds and for the collection of blood samples. Two groups of studies were performed.
Saline infusion The aim of these studies was to determine the effect on GH release of three consecutive administrations of saline, GHRH, EP92632 (Ala-His-D2Me-Trp-Ala-Trp-D-Phe-Lys-NH 2 ), a member of the GHRP family, or GHRH plus EP92632 during a continuous 6-h saline infusion (SALI). The present unavailability of hexarelin (9) dictated the use of a new GHRP, EP92632, which has a lower ef®cacy than but a similar potency to hexarelin (E max 32 ngaml and ED 50 145 mgakg vs E max 287 ngaml and ED 50 169 mgakg for EP92632 and hexarelin respectively; A E Rigamonti, unpublished results). Saline (4 ml/h) was infused intravenously from t 230 to t 360 , and a bolus of saline (0.1 ml/kg), GHRH (2 mg/kg; Geref, Serono, Rome, Italy), EP92632 (125 mg/kg; Europeptides, Argenteuil, France) or GHRH plus EP92632 was administered intravenously at t 60 , t 180 and t 360 . Blood samples for measurement of plasma GH concentrations were collected at t 230 , and t 0 , and then at 15-to 30-min intervals up to 360 min.
Somatostatin infusion
The aim of these studies was to determine the effects of three SS infusion withdrawals (SSIWs), consecutively performed, on the GH response to saline, GHRH, EP92632 or GHRH plus EP92632. Somatostatin (8 mg/(kgÂh)) was infused intravenously for 60 min, from t 0 to t 60 , from t 120 to t 180 and from t 240 to t 360 . At the termination of each SS infusion it was replaced by an infusion of saline, and a bolus injection of saline, GHRH, EP92632 or GHRH plus EP92632 was delivered, according to the above reported schedule. Blood samples for measurement of plasma GH were collected at t 230 and at 30-min intervals during SS infusion and at 15-min intervals during SALI up to 360 min.
GH radioimmunoassay
Blood samples were collected in tubes containing 0.15 mol/l EDTA and immediately chilled. Plasma was frozen until assayed for canine GH (cGH) by a double-antibody RIA. Highly puri®ed cGH (Pituitary Hormones and Antisera Center, Torrance, CA, USA), obtained together with the speci®c antibody anti-cGH through the courtesy of Dr A F Parlow, was used for iodination and as a standard. The sensitivity of the assay was 0.39 ng/ml. The intra-assay coef®cients of variation were 3.8 and 4.1% at concentrations of 12.5 and 3.1 ng/ml respectively. To avoid possible interassay variation, all samples of a given experiment were assayed in a single RIA. Table 1 ). Since no differences in hormone levels between male and female dogs were observed in the different experimental conditions as was the case in other studies (9), the data were pooled.
Statistical analysis
Statistical evaluation of differences in absolute GH concentrations and mean values of AUCs among the different experimental conditions were performed by the Student-Newman-Keuls test, preceded by one-way ANOVA. P , 0X05 was taken to be statistically signi®cant.
Results
Pro®les of mean plasma GH concentrations during the intravenous infusion of saline or SS, and bolus administration of saline or the compounds under study are shown in Figs. 1±4. Table 1 depicts schematically the extent of the GH responses to three cycles of SSIW or during SALI after application of GH secretagogs. In spite of the variability of standard errors of AUCs (Table 1) , the overall results obtained are sound. Table 1 Areas under the curve (AUC) of plasma GH concentrations versus time (means^S.E.M. ng/ml/min) from 5 dogs administered three consecutive boli of saline (0.1 ml/kg), GHRH (2 mg/kg iv), EP92632 (GHRP) (125 mg/kg iv), and GHRH plus EP92632, during a continuous 6-h saline infusion or three 1-h cycles of SS infusion alternated with saline infusions of the same duration. a P , 0X01 vs the respective AUC value (in the same cycle and with the same bolus injection) during saline infusion; b P , 0X01 vs the AUC value (in the same cycle) during saline infusion and saline bolus injection; c P , 0X01 vs the AUC value during saline infusion and GHRH bolus injection; d P , 0X01 vs the AUC 60±120 value during saline infusion and GHRP bolus injection; e P , 0X01 vs the AUC value during saline infusion and GHRP bolus injection; f P , 0X01 vs the AUC 60±120 value during saline infusion and GHRH plus GHRP bolus injection; g P , 0X01 vs the AUC 180±240 value during saline infusion and GHRH plus GHRP bolus injection; h P , 0X05 vs the respective AUC value during saline infusion; i P , 0X01 vs the respective AUC value during SS infusion and GHRP bolus injection.
The ®rst SSIW, concomitant with the bolus injection of saline, elicited a clear-cut plasma GH rise, whereas during SALI the same bolus injection failed to increase plasma GH titers AUC 60±120; SSIW 114X5^14X4 nga ml/min vs AUC 60±120; SALI 14X9^8X6 ngamlaminY P , 0X01X Similar signi®cant GH increments were observed after the second and third SSIWs (AUC 180±240; SSIW 111.7^10.8 ng/ml/min vs AUC 180±240; SALI 10.9^6.2 ng/ml/min, P , 0X01; AUC 300±360; SSIW 108X5^12X1 ngamlamin vs AUC 300±360; SAL 8. 45 .5 ng/ml/min, P , 0X01X No statistically signi®cant differences were found between the plasma GH rebound rises after each SSIW P NS ( Fig. 1; Table 1 ).
No spontaneous GH peak was observed during 6-h SALI after administration of saline boli, a ®nding in agreement with previous studies (33, 34) , since the experiments were performed at times unfavorable for spontaneous generation of GH peaks (35) .
Intravenous administration of the ®rst GHRH bolus during SALI induced a rise in plasma GH concentrations higher than that elicited by the bolus injection of saline AUC 60±120; SALI 222X4^98X2 ngamlamin vs AUC 60±120; SALI after saline bolus; P , 0X01X Under the same experimental conditions, the second GHRH bolus elicited a lower GH response AUC 180±240; SALI 81X7^59X5 ngamlamin vs AUC 60±120; SALI , P , 0X01Y while the amplitude of the third GHRH-evoked GH response was intermediate between the extent of the ®rst and second GHRH boli AUC 300±360; SALI 213X28 4X9 ngamlaminY vs AUC 60±120; SALI , P NSX SSIW induced a marked increase in the GH response to GHRH (AUC 60±120; SSIW 532.1^100.2 ng/ml/ min vs AUC 60±120; SALI , P , 0X01X In contrast, the second and third SSIWs did not increase the second and third plasma GH responses to GHRH bolus with respect to those occurring during SALI AUC 180±240; SSIW 165X8^73X9 ngamlamin vs AUC 180±240; SAL , P NS; AUC 300±360; SSIW 228.7^93.3 ng/ml/min vs AUC 300±360; SALI , P NS ( Fig. 2; Table 1 ).
EP92632, administered during SALI, induced a rise in plasma GH concentrations which was higher than those occurring after saline or GHRH bolus (AUC 60±120; SALI =940.6^136.9 ng/ml/min vs AUC 60±120; SALI after saline bolus, P , 0X01Y and vs AUC 60±120; SALI after GHRH bolus, P , 0X01X The second bolus of the peptide was followed by a GH peak of lesser amplitude AUC 180±240; SALI 418X0^105X2 ngaml/ min vs AUC 60±120; SALI , P , 0X01Y whereas there was a partial restoration of the GH response to the third EP92632 bolus which, however, did not reach statistical signi®cance compared with the response to the second bolus (AUC 300±360; SALI 580.3^119.1 ng/ml/min vs AUC 180±240; SALI , P NSX SSIW at the time of the ®rst EP92632 bolus injection strikingly enhanced the GH release elicited by the peptide (AUC 60±120; SSIW 1790.5^162.7 ng/ml/min vs AUC 60±120; SALI , P , 0X01X This pattern was also present, although to a lesser extent, with the second and third SSIWs AUC 180±240; SSIW 736X4^118X7 ngamlamin vs AUC 180±240; SALI , P , 0X01; AUC 300±360; SSIW 890X5^70X8 ngamlamin vs AUC 300±360; SALI , P , 0X05 (Fig. 3, Table 1 ).
Combined administration of GHRH and EP92632 during SALI induced a synergistic effect on GH release, which overrode any effect of previous GHRH or EP92632 results (AUC 60±120; SALI 2363.3^339.8 ng/ml/min vs AUC 60±120; SALI after saline, P , 0X01; vs AUC 60±120; SALI after GHRH, P , 0X01; vs AUC 60±120; SALI after EP92632, P , 0X01X A progressive reduction in the extent of the GH response was present after the second and the third GHRH plus EP92632 bolus injections (AUC 180±240; SALI 2210.9^151.6 ng/ml/ min vs AUC 60±120; SALI , P , 0X01; AUC 300±360; SALI =1353.8^248.4 ng/ml/min vs AUC 180±240; SALI , P , 0X01X
The GH response to the ®rst co-administration of the peptides was slightly increased after SSIW (AUC 60±120; SSIW 2946.0^280.0 ng/ml/min vs AUC 60±120; SALI , P , 0X05X In contrast, SSIW did not affect the GH rise evoked by the second bolus of GHRH plus EP92632 AUC 180±240; SSIW 1934X3^303X8 ngamlamin vs AUC 180±240; SALI , P NSY and a rather similar pattern was present after SSIW in the third GH response, although the difference compared with the results elicited during SALI was signi®cant (AUC 300±360; SSIW 2378.15 34.0 ng/ml/min vs AUC 300±360; SALI , P , 0X01 ( Fig. 4 ; Table 1 ).
No adverse side-effects were recorded during or after SS infusion or administration of GH secretagogs either alone or combined.
Discussion
An optimal pulsatile GH release requires the combination of pulsatile GHRH stimulation and a cyclic variation in the SS tone both to prevent leakage of pituitary GH and to maximize the GH pulse that can be secreted in a short time following the next GHRH pulse (28). Reportedly, SSIW either in animals (24±27) or humans (28±30) elicits a rebound GH rise which has been referred to a hypothalamic component, i.e. disinhibition of GHRH neuronal function (2, 4, 24, 26, 27, 29).
In our study, the repetition of SSIW was followed by equivalent GH secretory episodes, suggesting that this mechanism could have activated a physiological Figure 4 Plasma GH concentration pro®les (means^S.E.M., ng/ml) from 5 dogs administered three consecutive boli of GHRH (2 mg/kg ev) plus EP92632 (GHRP; 125 mg/kg iv).
mechanism which mimics that which normally controls GH pulse generation (28, 36). Exposure to three SS cycles of 1-h duration presumably simulates endogenous SS secretion and allows suf®cient GHRH to be synthesized at the hypothalamic level. Release of the same GHRH quantum induced by SSIW would be responsible for the uniform episodes of GH secretion detected at each SSIW cycle.
Based on the observation that the second and third GHRH boli delivered during SALI failed to elicit any sound GH rise (Fig. 2) ± as already reported in in vitro (37, 38) and in vivo (39, 40) studies ± the uniformity of GH release at each SSIW cycle appears to be a very interesting ®nding.
For GHRH, it has been argued that pituitary desensitization to repeated boli is responsible for the state of refractoriness (41), although depletion of a readily releasable pool sensitive to GHRH cannot be excluded (42) . A more likely explanation, however, rests on the induction of a GH negative auto-feedback elicited by the GH rise following the ®rst GHRH bolus. The increase in plasma GH concentrations would enhance hypothalamic SS tone (and probably reduce concomitantly the activity of GHRH-secreting neurons) (43±47), thus blunting the subsequent responsiveness to GHRH. Supporting this proposition is the ®nding that a cholinergic drug, pyridostigmine, which inhibits SS release (48) , given before the second GHRH bolus, reinstates GH responsiveness to the peptide in humans (49, 50) .
In the SSIW experiments in which GHRH was administered at the end of the ®rst cycle, the GH rebound was greater than in the saline-GHRH experiments. This was related, presumably, to the activation of GHRH pituitary`spare' receptors (28) rather than to the release of a maximal quantum of endogenous GHRH following SSIW. At the following SSIW cycles, the GH responses to GHRH were blunted and similar to those of the saline-GHRH experiments.
EP92632, a synthetic GHRP heptapeptide, exhibited a GH-releasing activity which was greater than that of GHRH; when combined with GHRH a striking synergistic effect was induced, the GH release following administration of both compounds being higher than the arithmetic sum of the GH rises induced by each compound given separately. Paradoxically, although there were unequivocal GH rises after each bolus of EP92632 alone, the GH-releasing effects of the second and third EP92632 boli were merely blunted, whereas the smaller GH response to GHRH had been nearly abolished (see above). Also, the GH responses to combined administration of EP92632 and GHRH were only slightly attenuated by the previous bolus.
Taken together, these data indicate that EP92632 probably counteracted the negative GH auto-feedback which activates somatostatinergic neurons, a proposition in keeping with the antagonistic action of GHRP on SS function (11, 51, 52).
In addition, inferential evidence has also been presented that GHRPs may play a role in SS action, functioning as SS antagonists at the pituitary level (53) . For instance, in conscious rats, continuous subthreshold infusion of GHRP-6, a GHRP compound, together with repeated injections of GHRH, induced GH responses that were uniform and greater in magnitude than those of rats given GHRH alone. Interestingly, interpeak serum GH concentrations were high between repeated GHRH boli, suggesting that GHRP-6 had reduced SS inhibitory in¯uences on the pituitary (52). Also, under our experimental conditions an antagonistic action of EP92632 on SS function at the pituitary level cannot be ruled out.
Regardless of the fact that the validity of these propositions needs to be veri®ed, and in contrast with the scarce reproducibility of the GHRH challenge (54, 55) , our study suggests that the repeatability of the GH response to multiple boli of a GHRP may be exploited clinically in GH hyposecretory states.
The most peculiar ®nding of this study was the clearcut enhancement of the EP92632-stimulated GH response present after each SSIW cycle. This fact, in view of the known functional interactions between GHRPs and GHRH, reinforces the proposition that SSIW disinhibits hypothalamic GHRH neurons, allowing a synergy of the exogenously administered GHRP with endogenously released GHRH (31, 56) . Since, reportedly, GHRPs promptly stimulate hypothalamic GHRH neurons (11, 57, 58), the biological effects of the endogenous GHRH release following SSIW could be further magni®ed.
In this context, it is noteworthy that co-administration of GHRH and EP92632 at the time of interruption of SS infusion barely increased the extent of the GH response over that following the combined administration of GHRP and GHRH during SALI, which would indicate that endogenous GHRH release triggered by SSIW was nearly maximal.
Recently, Cappa et al. (30) have demonstrated that SSIW elicits a signi®cant GH rise in normal control children (NC), but not in GH de®cient children, regardless of the underlying etiology, i.e. GH de®ciency (GHD) or GH neurosecretory dysfunction (GHND). This approach allowed complete discrimination of NC from GHD or GHND, but not of GHD from GHND children. Also Popovic et al. (59) have recently shown that combined administration of GHRH plus GHRP-6 only distinguishes healthy from GHD (and GHND) adults.
In patients with hypothalamic±pituitary disconnection, hexarelin, a potent GHRP in both animals and men (9, 60±64), failed to elicit a GH response, whereas it stimulated GH secretion in patients with GHND, with a lower inter-and intra-individual variability than that occurring with GHRH (65, 66).
In view of the results of our study, one wonders whether combined SSIW and GHRP injection may be a valid tool to distinguish GHD of hypothalamic origin from a combined hypothalamic/pituitary or a primary pituitary impairment. In fact, in GHD of hypothalamic origin SSIW plus GHRP bolus would induce a GH release intermediate between the one elicited in normal control children and that of children with hypothalamic/pituitary or primary pituitary impairment. Granted that the synergy of SSIW-exogenous GHRP is defective in hypothalamic subjects, GHRP still has the potential to stimulate speci®c GHRP receptors (13), to inhibit SS function (7, 23) and to act directly at the pituitary level (14, 15). GH release following SSIW and GHRP should be minimal or even absent in subjects with combined hypothalamic/pituitary or primary pituitary impairment.
If the ®ndings of our study could be extrapolated to humans, the GHRP challenge after SSIW, because of its effectiveness and safety, procedural simplicity and economy, might be a useful diagnostic tool in GHdependent growth disorders.
